Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:17:03 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



C:RVV - Revive Therapeutics Ltd. - http://www.revivethera.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
RVV - C  881.00.025·0.03282.00.025142.63150.025  0.03  0.0250.095  0.02Apr 18Apr 1815 min RT 2¢
CSE - C881.00.025·0.03282.00.03+0.00520.030.6190.025  0.03  0.0250.095  0.02Apr 1815 min
NEO ATS - U 0.02598.0230.025  0.025  0.025Apr 1815 min
Omega - O 0.03+0.00520.014.0030.03  0.03  0.03Apr 1815 min

Recent Trades - Last 10 of 15
Time ETExPriceChangeVolumeBuyerSellerMarkers
        
        
        
        
        
        
        
        
        
        

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolPriceTypeHeadline
2024-04-18 10:56C:RVV0.025News ReleaseRevive gets FDA acceptance for meeting request
2024-04-02 11:21C:RVV0.03News ReleaseRevive clinical study enrolls nearly 50% of sample
2024-03-27 13:25C:RVVNews ReleaseRevive submits meeting request to U.S. FDA
2024-03-19 10:11C:RVV0.03News ReleaseRevive receives notice to submit Type C meeting request
2024-03-12 09:42C:RVV0.035News ReleaseRevive recaps work on bucillamine, long COVID product
2024-02-28 18:51C:RVV0.025SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2024-02-28 18:51C:RVV0.025SEDAR Interim MD & ASEDAR Interim MD & A
2024-02-26 16:24C:RVV0.025News ReleaseRevive Therapeutics closes $1.18M final tranche
2024-02-01 11:25C:RVV0.03News ReleaseRevive proposes phase 2/3 bucillamine clinical study
2024-01-31 17:24C:RVV0.025News ReleaseRevive closes $913,500 first tranche of placement
2024-01-24 18:00C:RVV0.04News ReleaseRevive arranges $3-million private placement
2024-01-16 11:28C:RVV0.035News ReleaseRevive talks Bucillamine for nerve agent exposure
2024-01-10 10:07C:RVV0.035News ReleaseRevive develops new bucillamine formulation
2023-12-20 13:11C:RVV0.03News ReleaseRevive shareholders approve all matters at AGSM
2023-12-18 10:14C:RVV0.03News ReleaseRevive, Attwill to develop Bucillamine formulation
2023-11-29 19:43C:RVV0.03SEDAR Interim MD & ASEDAR Interim MD & A
2023-11-29 19:28C:RVV0.03SEDAR Interim Financial StatementsSEDAR Interim Financial Statements
2023-11-21 12:18C:RVV0.03News ReleaseRevive expects to complete bucillamine work by year-end
2023-11-06 10:30C:RVV0.03News ReleaseRevive unit, Lawson Health to develop long COVID tests
2023-10-27 21:18C:RVV0.03SEDAR MD & ASEDAR MD & A